Pharmaceutical economics and policy:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Oxford University Press
2007
|
| Ausgabe: | 2. edition |
| Schlagworte: | |
| Online-Zugang: | Publisher description Table of contents only Inhaltsverzeichnis |
| Beschreibung: | Includes bibliographical references and index |
| Beschreibung: | XIV, 336 Seiten Illustrationen |
| ISBN: | 0195300955 9780195300956 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV021840899 | ||
| 003 | DE-604 | ||
| 005 | 20200821 | ||
| 007 | t | ||
| 008 | 061205s2007 xxua||| |||| 00||| eng d | ||
| 010 | |a 2006003075 | ||
| 020 | |a 0195300955 |c cloth : alk. paper |9 0-19-530095-5 | ||
| 020 | |a 9780195300956 |9 978-0-19-530095-6 | ||
| 035 | |a (OCoLC)470957492 | ||
| 035 | |a (DE-599)BVBBV021840899 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c US | ||
| 049 | |a DE-12 |a DE-384 |a DE-19 |a DE-188 |a DE-526 |a DE-2070s | ||
| 050 | 0 | |a HD9666.5 | |
| 082 | 0 | |a 338.4/761510973 | |
| 084 | |a PN 991 |0 (DE-625)138350: |2 rvk | ||
| 084 | |a QR 525 |0 (DE-625)142044: |2 rvk | ||
| 100 | 1 | |a Schweitzer, Stuart O. |e Verfasser |0 (DE-588)171691121 |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical economics and policy |c Stuart O. Schweitzer |
| 250 | |a 2. edition | ||
| 264 | 1 | |a New York, NY |b Oxford University Press |c 2007 | |
| 300 | |a XIV, 336 Seiten |b Illustrationen | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 650 | 7 | |a Industrie pharmaceutique - États-Unis |2 ram | |
| 650 | 7 | |a Pharmacoéconomie - États-Unis |2 ram | |
| 650 | 7 | |a Politique pharmaceutique - États-Unis |2 ram | |
| 650 | 4 | |a Pharmaceutical industry |z United States | |
| 650 | 4 | |a Pharmaceutical policy |z United States | |
| 650 | 4 | |a Pharmaceutical industry | |
| 650 | 4 | |a Economics, Pharmaceutical |z United States | |
| 650 | 4 | |a Drug Industry |z United States | |
| 650 | 4 | |a Public Policy |z United States | |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelmarkt |0 (DE-588)4003131-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Strukturwandel |0 (DE-588)4058136-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Internationaler Vergleich |0 (DE-588)4120509-1 |2 gnd |9 rswk-swf |
| 651 | 4 | |a USA | |
| 651 | 7 | |a USA |0 (DE-588)4078704-7 |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 0 | 1 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 0 | 2 | |a Strukturwandel |0 (DE-588)4058136-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 1 | 1 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 1 | |5 DE-188 | |
| 689 | 2 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 2 | 1 | |a Arzneimittelmarkt |0 (DE-588)4003131-7 |D s |
| 689 | 2 | 2 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |D s |
| 689 | 2 | |5 DE-188 | |
| 689 | 3 | 0 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 3 | 1 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |D s |
| 689 | 3 | 2 | |a Internationaler Vergleich |0 (DE-588)4120509-1 |D s |
| 689 | 3 | |5 DE-188 | |
| 856 | 4 | |u http://www.loc.gov/catdir/enhancements/fy0639/2006003075-d.html |3 Publisher description | |
| 856 | 4 | |u http://www.loc.gov/catdir/toc/ecip067/2006003075.html |3 Table of contents only | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015052758&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015052758 | ||
Datensatz im Suchindex
| _version_ | 1804135775314378752 |
|---|---|
| adam_text | PHARMACEUTICAL ECONOMICS AND POLICY SECOND EDITION STUART O. SCHWEITZER
OXFORD UNIVERSITY PRESS 2007 CONTENTS INTRODUCTION 3 THE SUPPLY OF
PHARMACEUTICALS 5 THE DEMAND FOR PHARMACEUTICALS 1 PHARMACEUTICAL PRICES
8 THE MULTINATIONAL PHARMACEUTICAL INDUSTRY 11 INTERNATIONAL PRICE
COMPARISONS 12 TIMING OF PHARMACEUTICAL APPROVALS 12 GOVERNMENT
INTERVENTION IN THE PHARMACEUTICAL SECTOR 13 PART I. THE INDUSTRY 1 THE
PHARMACEUTICAL INDUSTRY 21 PHARMACEUTICAL RESEARCH AND DEVELOPMENT 22
THE COMPETITIVE STRUCTURE OF THE PHARMACEUTICAL INDUSTRY 23
PHARMACEUTICAL RESEARCH AND DEVELOPMENT AND PRICES 27 THE PHARMACEUTICAL
RESEARCH PROCESS 29 PRODUCT LIABILITY 38 CONCLUSIONS 40 2 THE
BIOTECHNOLOGY INDUSTRY 44 BACKGROUND 44 PRODUCT DEVELOPMENT IN THE
BIOTECHNOLOGY INDUSTRY 47 THE NATURAL HISTORY OF BIOTECHNOLOGY FIRMS 48
CASE STUDIES OF ALLIANCES 53 REGULATION 55 CASE STUDIES OF BIOTECHNOLOGY
FIRM GROWTH 57 CONCLUSIONS 60 XII CONTENTS OTHER FIRMS IN THE
PHARMACEUTICAL INDUSTRY 63 GENERIC DRUGS AND THEIR MANUFACTURERS 63
OUTSOURCING FIRMS 68 CONCLUSIONS 78 MARKETING PHARMACEUTICALS 82 SIZE OF
MARKETING EFFORT 85 DOES IT WORK? 85 TYPES OF PROMOTION 87 DISGUISING
MARKETING AS RESEARCH 93 MARKETING IN AN ERA OF MANAGED CARE 94 PHARMACY
BENEFIT MANAGERS 95 DIRECT-TO-CONSUMER ADVERTISING 97 OVER-THE-COUNTER
DRUGS 100 JOINT MARKETING 103 DISEASE MANAGEMENT 103 ROLES OF THE U.S.
FOOD AND DRUG ADMINISTRATION IN MARKETING 104 FALSE AND MISLEADING
CLAIMS 105 PART II. THE CONSUMER 5 THE DEMAND FOR PHARMACEUTICALS 115
HOW IS DEMAND DETERMINED? 116 THE CHANGING STRUCTURE OF THE
PHARMACEUTICAL MARKET ILL CONCLUSIONS 131 PART III. THE MARKET 6
PHARMACEUTICAL PRICES 137 THE PROBLEM OF PHARMACEUTICAL PRICES 138
PHARMACEUTICAL PRICES OVER TIME 139 MEASURING DRUG PRICES 141 HOW ARE
DRUG PRICES DETERMINED?. 143 COST STRUCTURE OF PHARMACEUTICAL FIRMS 144
IS THE PHARMACEUTICAL INDUSTRY MONOPOLISTIC? 149 HOW DRUG QUALITY
INFLUENCES PRICE 153 7 THE WORLDWIDE MARKET FOR PHARMACEUTICALS 157
GEOGRAPHIC PATTERNS OF PHARMACEUTICAL PRODUCTION AND SALES 158
PHARMACEUTICAL RESEARCH AND DEVELOPMENT: AN INTERNATIONAL VIEW 159 DOES
GOVERNMENT DRUG PRICE SETTING INFLUENCE R&D? 166 WORLDWIDE MANUFACTURING
AND SALES 167 ACCESS TO APPROPRIATE DRUGS IN DEVELOPING COUNTRIES 170
EFFECT OF THE WORLD TRADE ORGANIZATION TREATY 173 8 PRICING
PHARMACEUTICALS IN A WORLD ENVIRONMENT 177 WHY DO DRUG PRICES VARY
ACROSS COUNTRY? 178 COMPARISONS OF INTERNATIONAL DRUG PRICES 180 HOW DO
WE MEASURE DRUG PRICES ACROSS COUNTRIES? 18 4 CONTENTS XIII WHY DRUG
PRICE DIFFERENCES PERSIST 186 POLICY IMPLICATIONS 186 THE TIMING OF DRUG
APPROVALS IN THE UNITED STATES AND ABROAD 191 THE TIMING OF
PHARMACEUTICAL APPROVALS AND HEALTH POLICY 192 THE DRUG APPROVAL PROCESS
IN THE UNITED STATES 193 RECENT INITIATIVES TO EXPEDITE DRUG APPROVALS
198 IS THERE A U.S. DRUG LAG? 199 PART IV. INTERVENTION IN THE
PHARMACEUTICAL MARKET: PUBLIC AND PRIVATE 10 PHARMACEUTICAL REGULATION
AND COST CONTAINMENT BY THE PUBLIC SECTOR 209 EVOLUTION OF THE U.S. FOOD
AND DRUG ADMINISTRATION 210 MEDICAID 211 STATE COST-CONTAINMENT
EFFORTS 213 MEDICARE 214 11 REGULATION BY THE PRIVATE SECTOR 222
COST-CONTAINMENT MECHANISMS 111 COST CONTAINMENT IN MANAGED CARE 230 12
PHARMACEUTICAL REGULATION IN EUROPE 238 THE PHARMACEUTICAL INDUSTRY IN
EUROPE 238 HISTORY OF REGULATION IN EUROPE 239 MOVE TOWARD A SINGLE
MARKET 240 STRUCTURE AND ROLE OF THE EUROPEAN MEDICINES EVALUATION
AGENCY 240 DRUG REVIEW UNDER THE EUROPEAN MEDICINES EVALUATION AGENCY
241 CURRENT REGULATORY STRUCTURE 242 THE CENTRALIZED PROCEDURE FOR
MARKETING AUTHORIZATION 243 THE MUTUAL-RECOGNITION PROCEDURE 245
PERFORMANCE OF EUROPE S CENTRALIZED DRUG APPROVAL 246 RULES ON LABELING
OF MEDICINAL PRODUCTS 247 ADVERTISING REGULATIONS 248 PHARMACOVIGILANCE
248 GENERIC DRUGS 249 13 PATENT PROTECTION 252 PATENT LAW 253
PATENTABILITY AND PATENT CATEGORIES 254 HOW ARE PATENTS OBTAINED? 255
WHAT PROTECTION DOES A PATENT CONFER? 256 DURATION OF PATENT PROTECTION
256 INFRINGEMENT OF PATENTS 258 INTERNATIONAL PATENT TREATIES 258 PATENT
PROCEDURES UNDER INTERNATIONAL CONVENTIONS 260 SHORTCOMINGS OF THE
PATENT SYSTEM 260 PATENTS AND SOCIETAL CHOICE 261 SOCIAL BENEFITS OF THE
PATENT SYSTEM 261 XIV CONTENTS 14 EVALUATING NEW DRUGS 263 OPTIMIZING
PRODUCTION OF HEALTH 263 COST-BENEFIT ANALYSIS 266 COST-EFFECTIVENESS
ANALYSIS 270 COST-UTILITY ANALYSIS 272 POLICY APPLICATIONS 214
INTERPRETATION AND MISINTERPRETATION OF COST-EFFECTIVENESS STUDIES 277
15 COMPLEMENTARY AND ALTERNATIVE MEDICINES 280 WHO USES COMPLEMENTARY
AND ALTERNATIVE MEDICINES? 282 MANUFACTURERS AND DISTRIBUTORS OF
COMPLEMENTARY AND ALTERNATIVE MEDICINES 282 DIETARY SUPPLEMENTS 283 FOOD
ADDITIVES 293 MEDICAL FOODS 296 CONCLUDING REMARKS ON COMPLEMENTARY AND
ALTERNATIVE MEDICINES 300 16 PHARMACEUTICALS AND HEALTH POLICY: A LOOK
AHEAD 304 STRUCTURE OF THE PHARMACEUTICAL INDUSTRY 304 HEALTH SYSTEM
REFORM 306 DRUG PRICES 308 DRUG IMPORTS 308 PATENT PROTECTION 309 DRUG
APPROVALS 310 MANAGED CARE AND RESTRICTED ACCESS TO PHARMACEUTICALS 311
THE U.S. FOOD AND DRUG ADMINISTRATION 313 GENETICALLY TARGETED DRUGS 314
CONCLUSIONS 315 INDEX 317
|
| adam_txt |
PHARMACEUTICAL ECONOMICS AND POLICY SECOND EDITION STUART O. SCHWEITZER
OXFORD UNIVERSITY PRESS 2007 CONTENTS INTRODUCTION 3 THE SUPPLY OF
PHARMACEUTICALS 5 THE DEMAND FOR PHARMACEUTICALS 1 PHARMACEUTICAL PRICES
8 THE MULTINATIONAL PHARMACEUTICAL INDUSTRY 11 INTERNATIONAL PRICE
COMPARISONS 12 TIMING OF PHARMACEUTICAL APPROVALS 12 GOVERNMENT
INTERVENTION IN THE PHARMACEUTICAL SECTOR 13 PART I. THE INDUSTRY 1 THE
PHARMACEUTICAL INDUSTRY 21 PHARMACEUTICAL RESEARCH AND DEVELOPMENT 22
THE COMPETITIVE STRUCTURE OF THE PHARMACEUTICAL INDUSTRY 23
PHARMACEUTICAL RESEARCH AND DEVELOPMENT AND PRICES 27 THE PHARMACEUTICAL
RESEARCH PROCESS 29 PRODUCT LIABILITY 38 CONCLUSIONS 40 2 THE
BIOTECHNOLOGY INDUSTRY 44 BACKGROUND 44 PRODUCT DEVELOPMENT IN THE
BIOTECHNOLOGY INDUSTRY 47 THE NATURAL HISTORY OF BIOTECHNOLOGY FIRMS 48
CASE STUDIES OF ALLIANCES 53 REGULATION 55 CASE STUDIES OF BIOTECHNOLOGY
FIRM GROWTH 57 CONCLUSIONS 60 XII CONTENTS OTHER FIRMS IN THE
PHARMACEUTICAL INDUSTRY 63 GENERIC DRUGS AND THEIR MANUFACTURERS 63
OUTSOURCING FIRMS 68 CONCLUSIONS 78 MARKETING PHARMACEUTICALS 82 SIZE OF
MARKETING EFFORT 85 DOES IT WORK? 85 TYPES OF PROMOTION 87 DISGUISING
MARKETING AS RESEARCH 93 MARKETING IN AN ERA OF MANAGED CARE 94 PHARMACY
BENEFIT MANAGERS 95 DIRECT-TO-CONSUMER ADVERTISING 97 OVER-THE-COUNTER
DRUGS 100 JOINT MARKETING 103 DISEASE MANAGEMENT 103 ROLES OF THE U.S.
FOOD AND DRUG ADMINISTRATION IN MARKETING 104 FALSE AND MISLEADING
CLAIMS 105 PART II. THE CONSUMER 5 THE DEMAND FOR PHARMACEUTICALS 115
HOW IS DEMAND DETERMINED? 116 THE CHANGING STRUCTURE OF THE
PHARMACEUTICAL MARKET ILL CONCLUSIONS 131 PART III. THE MARKET 6
PHARMACEUTICAL PRICES 137 THE PROBLEM OF PHARMACEUTICAL PRICES 138
PHARMACEUTICAL PRICES OVER TIME 139 MEASURING DRUG PRICES 141 HOW ARE
DRUG PRICES DETERMINED?. 143 COST STRUCTURE OF PHARMACEUTICAL FIRMS 144
IS THE PHARMACEUTICAL INDUSTRY MONOPOLISTIC? 149 HOW DRUG QUALITY
INFLUENCES PRICE 153 7 THE WORLDWIDE MARKET FOR PHARMACEUTICALS 157
GEOGRAPHIC PATTERNS OF PHARMACEUTICAL PRODUCTION AND SALES 158
PHARMACEUTICAL RESEARCH AND DEVELOPMENT: AN INTERNATIONAL VIEW 159 DOES
GOVERNMENT DRUG PRICE SETTING INFLUENCE R&D? 166 WORLDWIDE MANUFACTURING
AND SALES 167 ACCESS TO APPROPRIATE DRUGS IN DEVELOPING COUNTRIES 170
EFFECT OF THE WORLD TRADE ORGANIZATION TREATY 173 8 PRICING
PHARMACEUTICALS IN A WORLD ENVIRONMENT 177 WHY DO DRUG PRICES VARY
ACROSS COUNTRY? 178 COMPARISONS OF INTERNATIONAL DRUG PRICES 180 HOW DO
WE MEASURE DRUG PRICES ACROSS COUNTRIES? 18 4 CONTENTS XIII WHY DRUG
PRICE DIFFERENCES PERSIST 186 POLICY IMPLICATIONS 186 THE TIMING OF DRUG
APPROVALS IN THE UNITED STATES AND ABROAD 191 THE TIMING OF
PHARMACEUTICAL APPROVALS AND HEALTH POLICY 192 THE DRUG APPROVAL PROCESS
IN THE UNITED STATES 193 RECENT INITIATIVES TO EXPEDITE DRUG APPROVALS
198 IS THERE A U.S. DRUG LAG? 199 PART IV. INTERVENTION IN THE
PHARMACEUTICAL MARKET: PUBLIC AND PRIVATE 10 PHARMACEUTICAL REGULATION
AND COST CONTAINMENT BY THE PUBLIC SECTOR 209 EVOLUTION OF THE U.S. FOOD
AND DRUG ADMINISTRATION 210 MEDICAID ' 211 STATE COST-CONTAINMENT
EFFORTS 213 MEDICARE 214 11 REGULATION BY THE PRIVATE SECTOR 222
COST-CONTAINMENT MECHANISMS 111 COST CONTAINMENT IN MANAGED CARE 230 12
PHARMACEUTICAL REGULATION IN EUROPE 238 THE PHARMACEUTICAL INDUSTRY IN
EUROPE 238 HISTORY OF REGULATION IN EUROPE 239 MOVE TOWARD A SINGLE
MARKET 240 STRUCTURE AND ROLE OF THE EUROPEAN MEDICINES EVALUATION
AGENCY 240 DRUG REVIEW UNDER THE EUROPEAN MEDICINES EVALUATION AGENCY
241 CURRENT REGULATORY STRUCTURE 242 THE CENTRALIZED PROCEDURE FOR
MARKETING AUTHORIZATION 243 THE MUTUAL-RECOGNITION PROCEDURE 245
PERFORMANCE OF EUROPE'S CENTRALIZED DRUG APPROVAL 246 RULES ON LABELING
OF MEDICINAL PRODUCTS 247 ADVERTISING REGULATIONS 248 PHARMACOVIGILANCE
248 GENERIC DRUGS 249 13 PATENT PROTECTION 252 PATENT LAW 253
PATENTABILITY AND PATENT CATEGORIES 254 HOW ARE PATENTS OBTAINED? 255
WHAT PROTECTION DOES A PATENT CONFER? 256 DURATION OF PATENT PROTECTION
256 INFRINGEMENT OF PATENTS 258 INTERNATIONAL PATENT TREATIES 258 PATENT
PROCEDURES UNDER INTERNATIONAL CONVENTIONS 260 SHORTCOMINGS OF THE
PATENT SYSTEM 260 PATENTS AND SOCIETAL CHOICE 261 SOCIAL BENEFITS OF THE
PATENT SYSTEM 261 XIV CONTENTS 14 EVALUATING NEW DRUGS 263 OPTIMIZING
PRODUCTION OF HEALTH 263 COST-BENEFIT ANALYSIS 266 COST-EFFECTIVENESS
ANALYSIS 270 COST-UTILITY ANALYSIS 272 POLICY APPLICATIONS 214
INTERPRETATION AND MISINTERPRETATION OF COST-EFFECTIVENESS STUDIES 277
15 COMPLEMENTARY AND ALTERNATIVE MEDICINES 280 WHO USES COMPLEMENTARY
AND ALTERNATIVE MEDICINES? 282 MANUFACTURERS AND DISTRIBUTORS OF
COMPLEMENTARY AND ALTERNATIVE MEDICINES 282 DIETARY SUPPLEMENTS 283 FOOD
ADDITIVES 293 MEDICAL FOODS 296 CONCLUDING REMARKS ON COMPLEMENTARY AND
ALTERNATIVE MEDICINES 300 16 PHARMACEUTICALS AND HEALTH POLICY: A LOOK
AHEAD 304 STRUCTURE OF THE PHARMACEUTICAL INDUSTRY 304 HEALTH SYSTEM
REFORM 306 DRUG PRICES 308 DRUG IMPORTS 308 PATENT PROTECTION 309 DRUG
APPROVALS 310 MANAGED CARE AND RESTRICTED ACCESS TO PHARMACEUTICALS 311
THE U.S. FOOD AND DRUG ADMINISTRATION 313 GENETICALLY TARGETED DRUGS 314
CONCLUSIONS 315 INDEX 317 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Schweitzer, Stuart O. |
| author_GND | (DE-588)171691121 |
| author_facet | Schweitzer, Stuart O. |
| author_role | aut |
| author_sort | Schweitzer, Stuart O. |
| author_variant | s o s so sos |
| building | Verbundindex |
| bvnumber | BV021840899 |
| callnumber-first | H - Social Science |
| callnumber-label | HD9666 |
| callnumber-raw | HD9666.5 |
| callnumber-search | HD9666.5 |
| callnumber-sort | HD 49666.5 |
| callnumber-subject | HD - Industries, Land Use, Labor |
| classification_rvk | PN 991 QR 525 |
| ctrlnum | (OCoLC)470957492 (DE-599)BVBBV021840899 |
| dewey-full | 338.4/761510973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/761510973 |
| dewey-search | 338.4/761510973 |
| dewey-sort | 3338.4 9761510973 |
| dewey-tens | 330 - Economics |
| discipline | Rechtswissenschaft Wirtschaftswissenschaften |
| discipline_str_mv | Rechtswissenschaft Wirtschaftswissenschaften |
| edition | 2. edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03186nam a2200769zc 4500</leader><controlfield tag="001">BV021840899</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20200821 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">061205s2007 xxua||| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2006003075</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0195300955</subfield><subfield code="c">cloth : alk. paper</subfield><subfield code="9">0-19-530095-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780195300956</subfield><subfield code="9">978-0-19-530095-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)470957492</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021840899</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-384</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-526</subfield><subfield code="a">DE-2070s</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HD9666.5</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/761510973</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PN 991</subfield><subfield code="0">(DE-625)138350:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QR 525</subfield><subfield code="0">(DE-625)142044:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schweitzer, Stuart O.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)171691121</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical economics and policy</subfield><subfield code="c">Stuart O. Schweitzer</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2. edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Oxford University Press</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV, 336 Seiten</subfield><subfield code="b">Illustrationen</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Industrie pharmaceutique - États-Unis</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacoéconomie - États-Unis</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Politique pharmaceutique - États-Unis</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical policy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Economics, Pharmaceutical</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Public Policy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelmarkt</subfield><subfield code="0">(DE-588)4003131-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Strukturwandel</subfield><subfield code="0">(DE-588)4058136-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Internationaler Vergleich</subfield><subfield code="0">(DE-588)4120509-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Strukturwandel</subfield><subfield code="0">(DE-588)4058136-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-188</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Arzneimittelmarkt</subfield><subfield code="0">(DE-588)4003131-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="2"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-188</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="2"><subfield code="a">Internationaler Vergleich</subfield><subfield code="0">(DE-588)4120509-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="5">DE-188</subfield></datafield><datafield tag="856" ind1="4" ind2=" "><subfield code="u">http://www.loc.gov/catdir/enhancements/fy0639/2006003075-d.html</subfield><subfield code="3">Publisher description</subfield></datafield><datafield tag="856" ind1="4" ind2=" "><subfield code="u">http://www.loc.gov/catdir/toc/ecip067/2006003075.html</subfield><subfield code="3">Table of contents only</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015052758&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015052758</subfield></datafield></record></collection> |
| geographic | USA USA (DE-588)4078704-7 gnd |
| geographic_facet | USA |
| id | DE-604.BV021840899 |
| illustrated | Illustrated |
| index_date | 2024-07-02T16:00:23Z |
| indexdate | 2024-07-09T20:45:52Z |
| institution | BVB |
| isbn | 0195300955 9780195300956 |
| language | English |
| lccn | 2006003075 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015052758 |
| oclc_num | 470957492 |
| open_access_boolean | |
| owner | DE-12 DE-384 DE-19 DE-BY-UBM DE-188 DE-526 DE-2070s |
| owner_facet | DE-12 DE-384 DE-19 DE-BY-UBM DE-188 DE-526 DE-2070s |
| physical | XIV, 336 Seiten Illustrationen |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Oxford University Press |
| record_format | marc |
| spelling | Schweitzer, Stuart O. Verfasser (DE-588)171691121 aut Pharmaceutical economics and policy Stuart O. Schweitzer 2. edition New York, NY Oxford University Press 2007 XIV, 336 Seiten Illustrationen txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index Industrie pharmaceutique - États-Unis ram Pharmacoéconomie - États-Unis ram Politique pharmaceutique - États-Unis ram Pharmaceutical industry United States Pharmaceutical policy United States Pharmaceutical industry Economics, Pharmaceutical United States Drug Industry United States Public Policy United States Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf Gesundheitspolitik (DE-588)4113743-7 gnd rswk-swf Arzneimittelmarkt (DE-588)4003131-7 gnd rswk-swf Strukturwandel (DE-588)4058136-6 gnd rswk-swf Internationaler Vergleich (DE-588)4120509-1 gnd rswk-swf USA USA (DE-588)4078704-7 gnd rswk-swf USA (DE-588)4078704-7 g Pharmazeutische Industrie (DE-588)4045696-1 s Strukturwandel (DE-588)4058136-6 s DE-604 DE-188 Arzneimittelmarkt (DE-588)4003131-7 s Gesundheitspolitik (DE-588)4113743-7 s Internationaler Vergleich (DE-588)4120509-1 s http://www.loc.gov/catdir/enhancements/fy0639/2006003075-d.html Publisher description http://www.loc.gov/catdir/toc/ecip067/2006003075.html Table of contents only GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015052758&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Schweitzer, Stuart O. Pharmaceutical economics and policy Industrie pharmaceutique - États-Unis ram Pharmacoéconomie - États-Unis ram Politique pharmaceutique - États-Unis ram Pharmaceutical industry United States Pharmaceutical policy United States Pharmaceutical industry Economics, Pharmaceutical United States Drug Industry United States Public Policy United States Pharmazeutische Industrie (DE-588)4045696-1 gnd Gesundheitspolitik (DE-588)4113743-7 gnd Arzneimittelmarkt (DE-588)4003131-7 gnd Strukturwandel (DE-588)4058136-6 gnd Internationaler Vergleich (DE-588)4120509-1 gnd |
| subject_GND | (DE-588)4045696-1 (DE-588)4113743-7 (DE-588)4003131-7 (DE-588)4058136-6 (DE-588)4120509-1 (DE-588)4078704-7 |
| title | Pharmaceutical economics and policy |
| title_auth | Pharmaceutical economics and policy |
| title_exact_search | Pharmaceutical economics and policy |
| title_exact_search_txtP | Pharmaceutical economics and policy |
| title_full | Pharmaceutical economics and policy Stuart O. Schweitzer |
| title_fullStr | Pharmaceutical economics and policy Stuart O. Schweitzer |
| title_full_unstemmed | Pharmaceutical economics and policy Stuart O. Schweitzer |
| title_short | Pharmaceutical economics and policy |
| title_sort | pharmaceutical economics and policy |
| topic | Industrie pharmaceutique - États-Unis ram Pharmacoéconomie - États-Unis ram Politique pharmaceutique - États-Unis ram Pharmaceutical industry United States Pharmaceutical policy United States Pharmaceutical industry Economics, Pharmaceutical United States Drug Industry United States Public Policy United States Pharmazeutische Industrie (DE-588)4045696-1 gnd Gesundheitspolitik (DE-588)4113743-7 gnd Arzneimittelmarkt (DE-588)4003131-7 gnd Strukturwandel (DE-588)4058136-6 gnd Internationaler Vergleich (DE-588)4120509-1 gnd |
| topic_facet | Industrie pharmaceutique - États-Unis Pharmacoéconomie - États-Unis Politique pharmaceutique - États-Unis Pharmaceutical industry United States Pharmaceutical policy United States Pharmaceutical industry Economics, Pharmaceutical United States Drug Industry United States Public Policy United States Pharmazeutische Industrie Gesundheitspolitik Arzneimittelmarkt Strukturwandel Internationaler Vergleich USA |
| url | http://www.loc.gov/catdir/enhancements/fy0639/2006003075-d.html http://www.loc.gov/catdir/toc/ecip067/2006003075.html http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015052758&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT schweitzerstuarto pharmaceuticaleconomicsandpolicy |